Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Closed Lower Than Its 50 Day Average


The stock last traded at $14.60 a tad below $15.51, the 50 day moving average and which is just a bit below the 200 day moving average of $15.13. The 50 day moving average moved down $-0.91 and the 200 day average moved down $-0.53. Trading volume for Atara Biotherapeutics, Inc. was 87K in the last trading session. Volume was down 57.24% under the stocks average daily volume.

Short traders are feeling a little more bullish on shares of the company of late if you take a look at the downtick in short interest. The company had a fall in short interest of -0.19% as of September 29, 2017 from the last reporting period. Short interest decreased from 4,499,130 to 4,490,478 over that period. Days to cover decreased from 27.0 to 26.0 and the percentage of shorted shares was 0.15% on September 29.

Here is a rundown on some insider market activity for Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Isaac E. Ciechanover, CEO sold $66,088 worth of shares at a price of $15.02 on October 12th. Ciechanover now owns $6,437,242 of stock per an SEC filing yesterday.

The following firms have recently changed their position in ATRA. As of the end of the quarter Neuberger Berman Group LLC had acquired a total of 131,465 shares growing its holdings by 15.7%. The value of the investment in (ATRA) went from $17,190,000 to $13,552,000 a change of 21.2% for the reporting period. As of quarter end Ubs Group Ag had bought 3 shares growing its position 17.6%. The value of the company’s investment in Atara Biotherapeutics, Inc. decreased from $0 to $0 decreasing nan% since the last quarter.

As of the end of the quarter Vident Investment Advisory, LLC had acquired a total of 34,933 shares growing its stake by 62.8%. The value of the investment in ATRA went from $1,144,000 to $1,268,000 a change of $124,000 quarter to quarter. As of the end of the quarter Cutler Group LP had disposed of a total of 2,500 shares trimming its stake by 89.3%. The value in dollars decreased from $39,000 to $0 decreasing 100.0% quarter over quarter.

In the latest earnings report the EPS was $-3.33 and is projected to be $-3.91 for the current year with 30,559,000 shares now outstanding. Next quarter’s EPS is expected be $-1.07 and the next full year EPS is projected to be $-4.36.

Atara Biotherapeutics, Inc., launched on August 22, 2012, is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. Cytotoxic T-cells, otherwise known as cytotoxic T lymphocytes (CTLs), can mount an immune response against an antigen or antigens in order to combat viral infection or disease..